Загрузка...
Leveraging National Cancer Institute Programmatic Collaboration for Single Radiopharmaceutical Drug Master Files
Targeted radiopharmaceutical conjugates intended for therapeutic use often are made of three key components, a decaying radionuclide, a chemical chelator/linker, and a targeted molecular entity. The National Cancer Institute (NCI) Experimental Therapeutics Program has accepted four radiopharmaceutic...
Сохранить в:
| Опубликовано в: : | Front Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6611355/ https://ncbi.nlm.nih.gov/pubmed/31316916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00573 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|